MUMBAI (Reuters) - India's second-largest drugmaker, Dr Reddy's Laboratories Ltd , reported a much lower-than-expected quarterly profit due to a write-off related to Venezuela's economic crisis which has damaged its business there.
Companies including Dr Reddy's have been trying for months to recover funds from OPEC member Venezuela as oil prices sink and food scarcity and power cuts stir public protest.
Dr Reddy's said it took a hit of 4.31 billion rupees ($65 million) in the January-March quarter because it could not get approval from the Venezuelan government to recover any more money beyond the $4 million it has already received.
As a result, profit slumped nearly 86 percent to 746 million rupees, while analysts polled by Thomson Reuters expected a profit of 5.52 billion rupees on average.
"We will continue to actively engage with the Venezuelan government to provide affordable medicine to fulfil the need of the people of the country, subject to repatriation of funds," Dr Reddy's Chief Executive GV Prasad said in a statement.
While revenues from North America, Dr Reddy's biggest market, rose 12 percent, and those from India were up 11 percent, they could not offset declining sales in Europe and emerging markets.
($1 = 66.6 Indian rupees)
(Reporting by Zeba Siddiqui in Mumbai; Editing by Subhranshu Sahu/Ruth Pitchford)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
